DD244345A5 - Neue peptide - Google Patents

Neue peptide Download PDF

Info

Publication number: DD244345A5
Authority: DD; German Democratic Republic
Prior art keywords: lys; insulin; human insulin; arg; thr
Prior art date: 1985-03-12

Application number

DD86287734A

Other languages

German (de)

English (en)

Inventor

Jan Markussen

Original Assignee

��@��@�a�k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-03-12

Filing date

1986-03-10

Publication date

1987-04-01

1986-03-10 Application filed by ��@��@�a�k�� filed Critical ��@��@�a�k��

1987-04-01 Publication of DD244345A5 publication Critical patent/DD244345A5/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 239
229940125396 insulin Drugs 0.000 claims abstract description 111
102000004877 Insulin Human genes 0.000 claims abstract description 93
108090001061 Insulin Proteins 0.000 claims abstract description 93
101000976075 Homo sapiens Insulin Proteins 0.000 claims abstract description 68
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 68
150000001413 amino acids Chemical class 0.000 claims abstract description 33
238000002360 preparation method Methods 0.000 claims abstract description 23
238000000034 method Methods 0.000 claims abstract description 22
230000007935 neutral effect Effects 0.000 claims abstract description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 11
230000008569 process Effects 0.000 claims abstract description 9
210000004899 c-terminal region Anatomy 0.000 claims abstract description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 70
150000001875 compounds Chemical class 0.000 claims description 64
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 62
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 57
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Natural products C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 41
229940024606 amino acid Drugs 0.000 claims description 33
235000001014 amino acid Nutrition 0.000 claims description 33
108010005991 Pork Regular Insulin Proteins 0.000 claims description 23
125000000539 amino acid group Chemical group 0.000 claims description 18
108090000631 Trypsin Proteins 0.000 claims description 12
102000004142 Trypsin Human genes 0.000 claims description 12
239000012588 trypsin Substances 0.000 claims description 12
125000003277 amino group Chemical group 0.000 claims description 11
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 8
239000004473 Threonine Substances 0.000 claims description 6
229960002898 threonine Drugs 0.000 claims description 6
230000001810 trypsinlike Effects 0.000 claims description 6
108090000790 Enzymes Proteins 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 5
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
102000007079 Peptide Fragments Human genes 0.000 claims description 4
108010033276 Peptide Fragments Proteins 0.000 claims description 4
150000003951 lactams Chemical class 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
229930064664 L-arginine Chemical group 0.000 claims description 3
235000014852 L-arginine Nutrition 0.000 claims description 3
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
235000013922 glutamic acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
238000005859 coupling reaction Methods 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
108010062796 arginyllysine Proteins 0.000 claims 1
230000008878 coupling Effects 0.000 claims 1
238000010168 coupling process Methods 0.000 claims 1
239000012634 fragment Substances 0.000 claims 1
125000004434 sulfur atom Chemical group 0.000 claims 1
230000002035 prolonged effect Effects 0.000 abstract description 19
230000009471 action Effects 0.000 abstract description 14
206010012601 diabetes mellitus Diseases 0.000 abstract description 7
150000002148 esters Chemical group 0.000 abstract description 7
102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
125000003368 amide group Chemical group 0.000 abstract description 4
239000000243 solution Substances 0.000 description 53
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 28
239000011701 zinc Substances 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 21
229910052725 zinc Inorganic materials 0.000 description 21
239000000203 mixture Substances 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
239000000047 product Substances 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 14
230000000694 effects Effects 0.000 description 14
239000002243 precursor Substances 0.000 description 14
235000018102 proteins Nutrition 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 12
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
239000013078 crystal Substances 0.000 description 12
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 12
239000000725 suspension Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 10
238000007792 addition Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
239000003480 eluent Substances 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
-1 aromatic hydroxy compound Chemical class 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
238000001962 electrophoresis Methods 0.000 description 8
239000004475 Arginine Substances 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000008103 glucose Substances 0.000 description 7
230000005012 migration Effects 0.000 description 7
238000013508 migration Methods 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
235000009697 arginine Nutrition 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000002425 crystallisation Methods 0.000 description 6
230000008025 crystallization Effects 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
239000004026 insulin derivative Substances 0.000 description 6
239000001103 potassium chloride Substances 0.000 description 6
235000011164 potassium chloride Nutrition 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
229960003767 alanine Drugs 0.000 description 5
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 5
239000001639 calcium acetate Substances 0.000 description 5
235000011092 calcium acetate Nutrition 0.000 description 5
229960005147 calcium acetate Drugs 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 5
239000004472 Lysine Substances 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
235000008521 threonine Nutrition 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
241000894007 species Species 0.000 description 3
239000000126 substance Substances 0.000 description 3
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
229940038773 trisodium citrate Drugs 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000025221 Humulus lupulus Species 0.000 description 2
235000008694 Humulus lupulus Nutrition 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010076181 Proinsulin Proteins 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
108010007568 Protamines Proteins 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000004554 glutamine Nutrition 0.000 description 2
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000012085 test solution Substances 0.000 description 2
239000004246 zinc acetate Substances 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 description 1
ATAFDSCDEDHMOK-UHFFFAOYSA-N 3,3-diaminopropanoic acid Chemical compound NC(N)CC(O)=O ATAFDSCDEDHMOK-UHFFFAOYSA-N 0.000 description 1
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000590035 Achromobacter lyticus Species 0.000 description 1
FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108010065691 Biphasic Insulins Proteins 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
240000003550 Eusideroxylon zwageri Species 0.000 description 1
XIPZDANNDPMZGQ-WHFBIAKZSA-N Gln-Cys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O XIPZDANNDPMZGQ-WHFBIAKZSA-N 0.000 description 1
COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100244921 Homo sapiens PRDX1 gene Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
102000005237 Isophane Insulin Human genes 0.000 description 1
108010081368 Isophane Insulin Proteins 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108010053229 Lysyl endopeptidase Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000201776 Steno Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101000993800 Sus scrofa Insulin Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
239000000189 biphasic insulin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
210000000080 chela (arthropods) Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000011188 deamidation reaction Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108091008695 photoreceptors Proteins 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229940119528 pork insulin Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
229960001153 serine Drugs 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DD86287734A 1985-03-12 1986-03-10 Neue peptide DD244345A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK113585A DK113585D0 (da)	1985-03-12	1985-03-12	Nye peptider

Publications (1)

Publication Number	Publication Date
DD244345A5 true DD244345A5 (de)	1987-04-01

Family

ID=8101410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD86287734A DD244345A5 (de)	1985-03-12	1986-03-10	Neue peptide

Country Status (22)

Country	Link
EP (1)	EP0194864B1 (fr)
JP (1)	JPS61212598A (fr)
KR (1)	KR930007433B1 (fr)
CN (1)	CN86101489A (fr)
AT (1)	ATE77391T1 (fr)
AU (1)	AU612964B2 (fr)
CS (1)	CS259536B2 (fr)
DD (1)	DD244345A5 (fr)
DE (1)	DE3685668T2 (fr)
DK (2)	DK113585D0 (fr)
ES (1)	ES8800276A1 (fr)
FI (1)	FI861007A7 (fr)
GR (1)	GR860687B (fr)
HU (1)	HU201097B (fr)
IL (1)	IL78103A0 (fr)
MY (1)	MY102102A (fr)
NO (1)	NO172441C (fr)
NZ (1)	NZ215445A (fr)
PH (1)	PH24260A (fr)
PT (1)	PT82173B (fr)
YU (1)	YU46001B (fr)
ZA (1)	ZA861432B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
DK347086D0 (da) *	1986-07-21	1986-07-21	Novo Industri As	Novel peptides
DK119785D0 (da) *	1985-03-15	1985-03-15	Nordisk Gentofte	Insulinpraeparat
DK437786D0 (da) *	1986-09-12	1986-09-12	Nordisk Gentofte	Insulinprecursorer
WO1990001038A1 (fr) *	1988-07-20	1990-02-08	Nordisk Gentofte A/S	Analogues d'insuline humaine et preparations les contenant
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) *	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) *	1989-03-20	1989-03-20	Nordisk Gentofte	Insulinforbindelser
US5130298A (en) *	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
DE3936876A1 (de) *	1989-11-06	1991-05-23	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
AUPP609198A0 (en) *	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
EP2033662B1 (fr)	2004-01-21	2012-10-17	Novo Nordisk Health Care AG	Conjugaison de peptides induite par la transglutaminase.
EP1969004B1 (fr)	2005-12-28	2011-08-10	Novo Nordisk A/S	Compositions renfermant une insuline acylée et du zinc et procédé de fabrication des dites compositions
DE102006031955A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
DE102008003566A1 (de) *	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko) *	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
RU2524423C2 (ru)	2008-01-09	2014-07-27	Санофи-Авентис Дойчланд Гмбх	Новые производные инсулина с чрезвычайно замедленным профилем время/действие
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
WO2011003820A1 (fr) *	2009-07-06	2011-01-13	Sanofi-Aventis Deutschland Gmbh	Préparations d'insuline stables à la chaleur et aux agitations
PH12011502708B1 (en)	2009-07-06	2017-11-10	Sanofi Aventis Deutschland	Insulin preparations containing methionine
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja)	2009-11-13	2015-12-16	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
AU2011252127B2 (en) *	2010-05-10	2014-02-20	Novo Nordisk A/S	Process for the preparation of insulin-zinc complexes
CN103179978A (zh)	2010-08-30	2013-06-26	赛诺菲-安万特德国有限公司	Ave0010用于制造供治疗2型糖尿病用的药物的用途
CN102174495A (zh) *	2011-01-20	2011-09-07	马忠仁	一种提取糜胰蛋白酶的方法
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja)	2011-08-29	2018-08-01	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK319780A (da) *	1980-07-24	1982-01-25	Forenede Bryggerier As	Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
DE3326472A1 (de) *	1983-07-22	1985-02-14	Hoechst Ag, 6230 Frankfurt	Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) *	1983-09-17	1985-04-25	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DK119785D0 (da) *	1985-03-15	1985-03-15	Nordisk Gentofte	Insulinpraeparat

1985
- 1985-03-12 DK DK113585A patent/DK113585D0/da unknown
1986
- 1986-02-26 ZA ZA861432A patent/ZA861432B/xx unknown
- 1986-02-27 PH PH33459A patent/PH24260A/en unknown
- 1986-03-10 DK DK107086A patent/DK158677C/da active
- 1986-03-10 DD DD86287734A patent/DD244345A5/de not_active IP Right Cessation
- 1986-03-10 YU YU34586A patent/YU46001B/sh unknown
- 1986-03-11 NZ NZ215445A patent/NZ215445A/xx unknown
- 1986-03-11 FI FI861007A patent/FI861007A7/fi not_active Application Discontinuation
- 1986-03-11 CN CN198686101489A patent/CN86101489A/zh active Pending
- 1986-03-11 DE DE8686301755T patent/DE3685668T2/de not_active Expired - Fee Related
- 1986-03-11 NO NO860920A patent/NO172441C/no unknown
- 1986-03-11 AU AU54495/86A patent/AU612964B2/en not_active Ceased
- 1986-03-11 AT AT86301755T patent/ATE77391T1/de not_active IP Right Cessation
- 1986-03-11 EP EP86301755A patent/EP0194864B1/fr not_active Expired - Lifetime
- 1986-03-11 IL IL78103A patent/IL78103A0/xx not_active IP Right Cessation
- 1986-03-11 KR KR1019860001737A patent/KR930007433B1/ko not_active Expired - Lifetime
- 1986-03-11 HU HU861024A patent/HU201097B/hu not_active IP Right Cessation
- 1986-03-11 CS CS861666A patent/CS259536B2/cs unknown
- 1986-03-11 JP JP61051586A patent/JPS61212598A/ja active Pending
- 1986-03-11 PT PT82173A patent/PT82173B/pt not_active IP Right Cessation
- 1986-03-11 ES ES552879A patent/ES8800276A1/es not_active Expired
- 1986-03-12 GR GR860687A patent/GR860687B/el unknown
1987
- 1987-09-30 MY MYPI87002520A patent/MY102102A/en unknown

Also Published As

Publication number	Publication date
MY102102A (en)	1992-03-31
EP0194864A3 (en)	1989-01-11
AU5449586A (en)	1986-09-18
PT82173B (pt)	1988-07-29
DE3685668T2 (de)	1993-01-14
FI861007L (fi)	1986-09-13
CN86101489A (zh)	1987-01-21
PH24260A (en)	1990-05-04
NZ215445A (en)	1989-07-27
PT82173A (en)	1986-04-01
FI861007A7 (fi)	1986-09-13
DK158677B (da)	1990-07-02
DK107086A (da)	1986-11-07
EP0194864A2 (fr)	1986-09-17
GR860687B (en)	1986-07-11
JPS61212598A (ja)	1986-09-20
NO172441C (no)	1993-07-21
ATE77391T1 (de)	1992-07-15
NO860920L (no)	1986-09-15
DK158677C (da)	1990-12-31
EP0194864B1 (fr)	1992-06-17
KR930007433B1 (ko)	1993-08-10
HU201097B (en)	1990-09-28
FI861007A0 (fi)	1986-03-11
DK113585D0 (da)	1985-03-12
ZA861432B (en)	1986-11-26
IL78103A0 (en)	1986-07-31
ES8800276A1 (es)	1987-11-01
KR860007288A (ko)	1986-10-10
YU46001B (sh)	1992-12-21
DK107086D0 (da)	1986-03-10
CS166686A2 (en)	1987-12-17
NO172441B (no)	1993-04-13
DE3685668D1 (en)	1992-07-23
HUT41052A (en)	1987-03-30
AU612964B2 (en)	1991-07-25
CS259536B2 (en)	1988-10-14
YU34586A (en)	1988-10-31
ES552879A0 (es)	1987-11-01

Legal Events

Date	Code	Title	Description
1995-07-06	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE3685668T2 (de)	1993-01-14	Peptide.
DE3788684T2 (de)	1994-05-19	Peptide.
DE69722397T2 (de)	2004-04-01	Insulin-derivate und ihre verwendung
EP0132769B1 (fr)	1988-01-07	Produit pharmaceutique pour le traitement du diabète mellitus
EP0885961B1 (fr)	2004-12-01	Nouveaux dérivés de l'insuline avec déclenchement d'action rapide
DE3880346T2 (de)	1993-07-29	Insulinderivate.
EP0132770B1 (fr)	1987-09-16	Dérivés de l'insuline, procédés pour leur préparation, leur utilisation et compositions pharmaceutiques pour le traitement du diabète mellitus
DE69631996T2 (de)	2005-01-27	Verfahren zur Herstellung von acylierten Proteinpuder
EP2229407B1 (fr)	2016-11-16	Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
DE69529708T2 (de)	2003-10-16	Herstellung von stabilen Zink-Insulinanalogen-Kristallen
DE69629210T2 (de)	2004-04-22	Insulinabkömmlinge
AT408611B (de)	2002-01-25	Insulinanalogon-protamin-komplex
DE69816409T2 (de)	2004-06-09	Kristallines Parathyroidhormon
DE3687500T2 (de)	1993-07-01	Insulinabkoemmlinge und arzneimittel die diese enthalten.
EP0821006B1 (fr)	2004-04-21	Dérivés de l'insuline ayant une activité de liaison au zinc augmentée
DE2600971C2 (de)	1985-12-12	Verfahren zur Herstellung von Rinder-Insulin-Komplexen mit Dauerwirkung und diese Komplexe enthaltende Arzneimittel
DE102008003566A1 (de)	2009-07-16	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009087082A2 (fr)	2009-07-16	Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
EP0368187A2 (fr)	1990-05-16	Dérivés d'insuline, leur emploi et une composition pharmaceutique les contenant
DE3587227T2 (de)	1993-08-12	Antidiabetikaverbindungen.
EP1084248A2 (fr)	2001-03-21	Nouveaux analogues de l'insuline presentant un pouvoir de liaison accru avec le zinc
DE102008025008A1 (de)	2009-11-26	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE3587226T2 (de)	1993-08-05	Antidiabetikaverbindungen.
DE69829953T2 (de)	2006-03-02	Kristallisation von proteinen
EP0622376B1 (fr)	2001-08-08	Amorphes formes monosphériques de dérivés d'insuline